TNFSF10 and Miyoshi myopathy: To determine whether TRAIL (alone or in combination with DOX) is also effective at inducing anti-myeloma activity in vivo we used the NOD/SCID mouse xenograft model of subcutaneous plasmacytoma growth initiated by implanting separated MM CD138− cells (Fig. 10).